The annual meeting this year focuses on predictability and prediction of Adverse Reactions related to target organs in early drug development, starting with an exciting plenary lecture of Sir Munir Pirmohamed about hypersensitivity and adverse drug reactions. Hot topics are prediction of ADRs in kidney, liver, CNS and the heart followed by local ADRs and immune system.
This meeting is a must-attend event for everyone involved in planning and realisation of early phase trials.
We tested regorafenib eye drops in healthy subjects to assess ophthalmic tolerability, safety and systemic exposure. This is the first time regorafenib was administered to the eye. For details see the recently published paper in the British Journal of Clinical Pharmacology.
All speakers for the 3rd GBHI conference have been confirmed!
The main topics selected for this year’s conference are: Necessity of multiple dose studies in BE testing, BE of Transdermal Delivery Systems, and BE of liposomal parenteral preparations. In addition, unresolved thematic aspects from the previous conference will be taken up again with the intention to achieve further consensus.
The conference takes place in Amsterdam from April 12-13, 2018. For more information, please visit the official website.
We look forward to meeting you in April!